Guideline

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)

Read time: 1 mins

Last updated:1st Sep 2024

Source: SEOM (Spanish Society of Medical Oncology), GETNE (Grupo Español de Tumores Neuroendocrinos y Endocrinos) & TTCC (Grupo Español de Tumores de Cabeza y Cuello)

Availability: Free full text

Status: Current

SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023) - SEOM (Spanish Society of Medical Oncology), GETNE (Grupo Español de Tumores Neuroendocrinos y Endocrinos) & TTCC (Grupo Español de Tumores de Cabeza y Cuello)

Thyroid cancer (TC) represents 3% of global cancer incidence. Recent changes have optimized treatment decisions based on risk assessment, molecular profiling, and imaging assessment, leading the development of targeted agents that have modified the natural history of this disease. This increasing complexity on treatment options requires careful assessment at the different stages of the disease to provide the most suitable approach from diagnosis to long-term follow-up. This guideline aims to offer a comprehensive and practical overview on the current status and last updates of TC management.

Read full Guideline